Ocugen Stock Receives 'Moderate Buy' Rating from Analysts

Analysts see promise in the biotech company's gene therapy and vaccine pipeline.

Apr. 11, 2026 at 8:13am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, industrial banking and financial machinery, representing the complex systems and infrastructure that support the biotech industry without using literal currency or charts.Ocugen's gene therapy and vaccine pipeline is drawing increased attention from Wall Street, though challenges remain in the competitive biotech landscape.Malvern Today

Shares of Ocugen, Inc. (NASDAQ:OCGN) have received an average 'Moderate Buy' rating from the five analysts covering the company, according to Marketbeat Ratings. One analyst has a 'sell' recommendation, while four have assigned 'buy' ratings, with an average 12-month price target of $9.75.

Why it matters

Ocugen is a clinical-stage biotech company focused on developing gene therapies for rare inherited retinal diseases as well as novel vaccines. The 'Moderate Buy' rating from analysts suggests they see potential in the company's pipeline, even as one analyst remains cautious.

The details

The analysts' ratings come as Ocugen continues to advance multiple gene therapy programs targeting retinal disorders, while also leveraging strategic partnerships to broaden its vaccine portfolio. The company's stock has traded in a range of $0.64 to $2.73 over the past 52 weeks.

  • Ocugen reported its latest quarterly results on March 4, 2026.

The players

Ocugen, Inc.

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases.

Cora Capital Advisors LLC

A hedge fund that has added to its stake in Ocugen, now owning 30,143 shares.

Jain Global LLC

A hedge fund that has increased its position in Ocugen to 114,690 shares.

Got photos? Submit your photos here. ›

The takeaway

Ocugen's 'Moderate Buy' rating from analysts suggests the company's gene therapy and vaccine pipeline holds promise, even as one analyst remains cautious. The biotech firm will need to continue advancing its clinical programs and partnerships to capitalize on this potential.